8-K: CooperCompanies Reports Q3 2025 Results, Raises EPS Guidance

CooperCompanies announced its fiscal third quarter 2025 financial results, reporting a 6% revenue increase and raising its full fiscal year non-GAAP diluted EPS guidance.

Summary

• Revenue increased 6% year-over-year to $1,060.3 million for the fiscal third quarter ended July 31, 2025.
• CooperVision (CVI) revenue rose 6% to $718.4 million, and CooperSurgical (CSI) revenue increased 4% to $341.9 million.
• GAAP diluted earnings per share (EPS) was $0.49, a 6% decrease from the prior year's third quarter.
• Non-GAAP diluted EPS was $1.10, a 15% increase from the prior year's third quarter.
• Cash provided by operations was $261.5 million, with free cash flow of $164.6 million after $96.9 million in capital expenditures.
• The company repurchased $52.1 million of common stock, approximately 724.3 thousand shares, at an average share price of $71.97, with $163.6 million remaining in the existing share repurchase program.

Sentiment

Score: 7

Explanation: While revenue was below expectations and GAAP EPS declined, the strong non-GAAP EPS growth, robust free cash flow, and raised earnings guidance, coupled with management's confidence and strategic drivers like MyDay, indicate a generally positive operational performance and outlook despite some top-line challenges.

Positives

• Non-GAAP diluted EPS increased 15% year-over-year to $1.10, demonstrating strong earnings growth.
• Delivered strong margins, with non-GAAP gross margin up 70 basis points to 67% and non-GAAP operating margin up 60 basis points to 26%.
• Generated robust free cash flow of $164.6 million.
• Raised fiscal year 2025 non-GAAP diluted EPS guidance to $4.08 $4.12, reflecting operational performance.
• Management expects improving revenue in Q4 and fiscal 2026, driven by the MyDay product line.
• Interest expense decreased to $25.4 million from $28.5 million in the prior year, attributed to lower average interest rates and lower average debt.

Negatives

• Revenues were below expectations.
• GAAP diluted EPS decreased 6% year-over-year to $0.49.
• GAAP gross margin decreased to 65% from 66% in the prior year, primarily due to a product line exit at CooperSurgical.
• GAAP operating margin decreased to 17% from 19% in the prior year, also primarily due to a product line exit at CooperSurgical.

Risks

• Adverse changes in global or regional general business, political, and economic conditions, including international conflicts, natural disasters, and pandemic conditions.
• Impact of international conflicts on the global and local economy, financial markets, energy markets, currency rates, and the ability to supply products.
• Challenges of managing substantial and expanding international operations and complying with diverse legal, compliance, and regulatory requirements.
• Actual imposition or threats of tariffs, customs duties, and other retaliatory trade actions.
• Foreign currency exchange rate and interest rate fluctuations, including the impact of rate increases on variable rate indebtedness.
• Changes in tax laws, examinations by tax authorities, and changes in the geographic composition of income.
• Acquisition-related adverse effects, such as failure to achieve anticipated benefits, integration delays or costs, and issues with regulatory approvals.
• Compliance costs and potential liability related to U.S. and foreign privacy and healthcare regulations (e.g., HIPAA, CCPA, GDPR), including data security breaches.
• Major disruptions in manufacturing, accounting, financial reporting, research and development, or distribution facilities due to integration challenges, disasters, cybersecurity incidents, or third-party vendor failures.
• Market consolidation of large customers globally, resulting in a larger proportion or concentration of business from fewer customers.
• Disruptions in supplies of raw materials, particularly components used to manufacture silicone hydrogel lenses.
• New U.S. and foreign government laws and regulations, and changes in existing laws, affecting the healthcare, contact lens, medical device, or pharmaceutical industries (e.g., EU Medical Devices Regulation (MDR), EU In Vitro Diagnostic Medical Devices Regulation (IVDR)).
• Legal costs, insurance expenses, settlement costs, and the risk of adverse decisions related to product liability, patent infringement, contractual disputes, or other litigation.
• Limitations on sales following product introductions due to poor market acceptance.
• New competitors, product innovations or technologies, and competitors' expansion through acquisitions.
• Reduced sales, loss of customers, reputational harm, and costs from product recalls and warning letters.
• Failure to receive, or delays in receiving, regulatory approvals or certifications for products.
• Failure of customers and end users to obtain adequate coverage and reimbursement from third-party payers for products and services.
• Requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets, and idle manufacturing facilities and equipment.
• The success of research and development activities and other start-up projects.
• Dilution to earnings per share from acquisitions or issuing stock.
• Impact and costs incurred from changes in accounting standards and policies.
• Risks related to environmental laws and requirements applicable to facilities, products, or manufacturing processes, including evolving regulations regarding hazardous substances.
• Risks related to environmental, social, and corporate governance (ESG) issues, including regulatory and disclosure requirements, climate change, and sustainability.

Future Outlook

The company updated its fiscal year 2025 financial guidance, projecting total revenue of $4,076 $4,096 million (4% to 4.5% organic growth) and non-GAAP diluted EPS of $4.08 $4.12. For the fiscal fourth quarter 2025, total revenue is expected to be $1,049 $1,069 million (2% to 4% organic growth) with non-GAAP diluted EPS of $1.10 $1.14. Management anticipates improving revenue in Q4 and fiscal 2026, driven by the MyDay product line.

Management Comments

• "I'm pleased to report that we delivered strong margins, double-digit earnings growth, and robust free cash flow reflecting the operational excellence that remains central to our growth strategy."
• "Our revenues were below expectations but we're raising earnings guidance to reflect our operational performance and expect improving revenue in Q4 and in fiscal 2026 driven by MyDay."
• "We remain confident in our strategy and ability to deliver long-term shareholder value."

Industry Context

CooperCompanies operates in the global medical device sector, specifically in contact lenses (CooperVision) and women's healthcare/fertility (CooperSurgical). The focus on operational excellence, efficiency gains, and strategic product drivers like MyDay aligns with broader industry trends emphasizing profitability and innovation amidst varying market conditions. The company's substantial international presence and exposure to foreign currency fluctuations are common for global medical device firms.

Comparison to Industry Standards

• The 6% year-over-year revenue growth is solid, but the 'below expectations' comment suggests it might be trailing some faster-growing segments or competitors in the medical device space, which often see higher single-digit or double-digit growth for innovative products.
• The non-GAAP gross margin of 67% and operating margin of 26% demonstrate strong profitability, which is generally competitive within the medical device industry, often characterized by high R&D and regulatory costs but also strong pricing power for specialized products.
• The 15% non-GAAP EPS growth is robust and indicates effective cost management and operational leverage, potentially outperforming peers facing similar revenue headwinds.
• The share repurchase program and robust free cash flow generation are positive signs of financial health and shareholder return focus, comparable to well-established, mature medical device companies.

Legal Proceedings

• Risks include legal costs, insurance expenses, settlement costs, and the risk of adverse decisions related to product liability, patent infringement, contractual disputes, or other litigation.
• Charges in the three months ended July 31, 2025, included $2.4 million related to legal matters.

Stakeholder Impact

• Shareholders: Positive impact from strong non-GAAP earnings growth, robust free cash flow, raised earnings guidance, and ongoing share repurchase program. Potential concern regarding revenue being below expectations and GAAP EPS decline.
• Employees: Operational excellence and efficiency gains could imply ongoing focus on productivity, potentially impacting workforce structure.
• Customers: Continued focus on product innovation (e.g., MyDay) and operational excellence aims to deliver high-quality medical devices.
• Creditors: Lower average interest rates and lower average debt contribute to a healthier financial position.

Next Steps

• Host an audio webcast and conference call on August 27, 2025, at 5:00 PM ET to discuss results and corporate developments.
• Focus on improving revenue in Q4 and fiscal 2026, driven by MyDay.
• Continue share repurchases under the existing program, which has $163.6 million remaining availability.

Key Dates

Recommendation

While the company demonstrated strong operational performance, evidenced by double-digit non-GAAP EPS growth, robust free cash flow, and raised earnings guidance, the reported revenues were below expectations. This mixed performance, with strong profitability offsetting top-line softness, suggests a 'hold' recommendation. Investors should monitor the company's ability to accelerate revenue growth in Q4 and fiscal 2026, particularly with the anticipated contribution from MyDay, to justify a more aggressive stance. The share repurchase program provides some support, but the underlying revenue trajectory needs to improve consistently.

Keywords

medical device, contact lenses, women's healthcare, fertility, CooperVision, CooperSurgical, Q3 earnings, financial results, EPS guidance, revenue growth, free cash flow, share repurchase, MyDay